Table 1 Patient demographics
|  | Critically ill, septic (n = 22) | Critically ill, non-septic (n = 10) |
|---|---|---|
Age, mean (range) | 58 (31–91) | 72 (59–88) |
Sex | Â | Â |
Female | 15 (68.2%) | 5 (50%) |
Race | Â | Â |
African American | 0 | 2 (20%) |
White | 20 (90.0%) | 8 (80%) |
Asian | 1 (4.5%) | 0 |
Hispanic | 1 (4.5%) | 0 |
Medical comorbidities | Â | Â |
Cancer | 8 (36.4%) | 3 (30%) |
Cardiovascular disease | 12 (54.5%) | 7 (70%) |
Peripheral vascular disease | 3 (13.6%) | 3 (30%) |
Diabetes | 9 (40.9%) | 3 (30%) |
Gastrointestinal disease | 7 (31.8%) | 4 (40%) |
Hepatic disease | 1 (4.5%) | 1 (10%) |
Hyperlipidemia | 9 (40.9%) | 5 (50%) |
Hypertension | 12 (54.5%) | 6 (60%) |
Kidney or urologic disease | 8 (36.4%) | 3 (30%) |
Cerebrovascular or neurologic disease | 8 (36.4%) | 3 (30%) |
Obesity | 6 (27.3%) | 5 (50%) |
Respiratory disease | 7 (31.8%) | 5 (50%) |
Substance abuse | 0 | 1 (10%) |
Thyroid disease | 5 (22.7%) | 3 (30%) |
Severity of illness | Â | Â |
APACHE II score | 23 ± 6.2 | 25.3 ± 4.7 |
SOFA score | 8 ± 3.5 | 8 ± 3.1 |
Charlson Comorbidity Index | 6 ± 2.9 | 6.4 ± 2.4 |
Patients receiving stress-dosed hydrocortisone (n) | 4 (18%) | 0 |
Mean daily hydrocortisone dose amongst recipients (mg) | 137 ± 36 | - |
Mean duration of hydrocortisone amongst recipients (d)* | 5.3 ± 3.0 | – |
Laboratory values | Â | Â |
Leukocyte count (× 103/µl) | 21.184 ± 10.5 | 13.797 ± 9.8 |
Absolute lymphocyte count (× 103/µl) | 0.889 ± .63 | 1.845 ± 1.9 |
Absolute monocyte count (× 103/µl) | 0.938 ± .71 | 1.528 ± .70 |
Lactic acid (mg/dL) on admission | 4.000 ± 3.5 | 2.528 ± 1.4 |
Shock (lactate > 2) on admission (n) | 5 (22.7%) | 0 |
30-Day outcomes | Â | Â |
Secondary infections (n, %) | 4 (18.2%) | 1 (10%) |
Secondary infection with gram negative (n, %) | 2 (9.1%) | 0 |
In-hospital mortality rate (n, %) | 7 (31.8%) | 1 (4.5%) |
30-Day mortality rate (n, %) | 7 (31.8%) | 1 (4.5%) |
Mean hospital length of stay (days) | 11.8 ± 6.4 | 14.3 ± 5.3 |
Mean ECOG/Zubrod score at hospital discharge | 3 ± 1.9 | 3.1 ± 1.4 |
Mean ECOG/Zubrod Score at 30 Days | 2.7 ± 1.3 | 2 ± 1.6 |
Hospital readmission rate (n, %) | 2 (9.1%) | 1 (4.5%) |
Mean length of antibiotic therapy (days) | 11.1 ± 6.9 | 4.3 ± 4.8 |
Long-term outcomes | Â | Â |
Death-free days until follow-up (days) | 112 ± 98.2 | 173.3 ± 89.2 |
Discharged to nursing facility or long-term acute care hospital (n, %) | 7 (32%) | 5 (50%) |